Cocaine abuse vaccine TA-CD
Alternative Names: TA-CD; TA-CD09Latest Information Update: 26 Jun 2015
At a glance
- Originator ImmuLogic Pharmaceutical
- Developer Celtic Pharma
- Class Drug withdrawal therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cocaine-related disorders
Most Recent Events
- 31 Aug 2010 Celtic Pharma and the National Institute on Drug Abuse initiate a phase II trial for Cocaine abuse in USA
- 21 Jun 2006 Interim results from a phase IIb clinical trial in cocaine abuse have been added to the Drug Withdrawal therapeutic trials section
- 17 Jun 2004 Clinical data from a media release have been added to the Drug Withdrawal immunogenicity and therapeutic trials sections